DUPIXENT®

(Dupliumab)

Documentation

Patented
Approved 2017
FDA Letter
FDA Label
Full Sequence

Brief Summary

Function Type: Antagonist
Target: IL-4Rα
Indication Category: Autoimmunity

Approved Indications

Detailed Summary

Side Effects

References

Wikipedia
Drugs.com
FDA